// App-Quantinova.ai

e20003 : Possible utility of actinin-4 as a predictive biomarker of the efficacy of postoperative adjuvant chemotherapy for completely resected early stage lung adenocarcinoma.

Researchers

Presenter

  • Hideaki Shiraishi

Principal Investigators

  • Yutaka Fujiwara

  • Takanori Kakuya

  • Nami Miura

  • Yukio Watabe

  • Rintaro Noro

  • Koji Tsuta

  • Fumihiko Kakizaki

  • Masahiro Kamita

  • Hirokazu Shoji

  • Wilber Huang

  • Shun-ichi Watanabe

  • Tesshi Yamada

  • Yuichiro Ohe

  • Kazufumi Honda

Medical Centers

  • National Cancer Center Hospital, Tokyo, Japan

  • Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Tokyo, Japan

  • National Cancer Center Research Institute, Tokyo, Japan

  • Nippon Medical School, Tokyo, Japan

  • Division of Chemotherapy and Clinical Research, National Cancer Center Research Institute, Tokyo, Japan

  • Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan

  • ABNOVA, Taipei, Taiwan

  • Division of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan

  • National Cancer Center Research Institute, Tokyo, Japan

Locations

  • Taiwan

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • Alpha-Actinin 4

  • Apparent diffusion coefficient

Drug/Treatment

  • Vinorelbine

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved